GRAL Stock Chart & Stats
$825.00
$0.00(0.00%)
At close: 4:00 PM EDT
$825.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$582.21 - $1,997.99
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$50.96B
Enterprise Value$2.17K
Total Cash (Recent Filing)$861.61M
Total Debt (Recent Filing)$91.31M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Nov 18, 2026EPS Estimate
-45.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.75
Shares Outstanding42,916,590
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.22
Price to Sales (P/S)21.37
P/FCF Ratio-10.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,189.55Price Target Upside44.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue And Volume GrowthConsistent double-digit revenue and test-volume growth demonstrates durable commercial adoption and expanding customer reach. Higher volumes provide fixed-cost leverage, improve unit economics over time, and create a larger installed base that supports recurring revenue and bargaining power with payers and providers.
Low Leverage And Sizable Asset BaseA very low debt load and substantial assets give the company financial flexibility to fund clinical programs, regulatory activities and sales expansion without near-term refinancing pressure. This balance-sheet strength reduces solvency risk while management executes commercialization and approval milestones.
Robust Clinical Evidence And Test DifferentiationLarge-scale, interventional trial evidence and low false-positive rates create a durable competitive moat versus peers relying on case-control data. Strong clinical performance supports regulatory approvals, payer coverage conversations, provider trust, and lower downstream diagnostic costs, aiding long-term adoption.
Bears Say
Negative Gross Profit And Large Operating LossesPersistent negative gross margins and very large operating losses mean the business still consumes substantial cash to scale. Until gross profit turns sustainably positive and operating leverage narrows, the company will rely on external funding and face ongoing dilution or strategic constraint on growth investments.
Regulatory Timing And Advisory Committee RiskOutcome and timing of FDA review and the upcoming advisory committee are material binary events that will determine market access and payer willingness. Delays or unfavorable panel feedback could postpone broad coverage and scale, prolonging reliance on self-pay and slowing durable commercial expansion.
Upcoming Royalty Resumption Pressures MarginsResumption of a roughly 7% Illumina royalty is a structural cost that will compress future gross margins and reduce unit economics at scale. This recurring expense raises the bar for eventual profitability and could limit reinvestment capacity unless offset by higher prices or materially lower underlying costs.
GRAIL Inc News
GRAL FAQ
What was Grail Inc’s price range in the past 12 months?
Grail Inc lowest stock price was $582.21 and its highest was $1997.99 in the past 12 months.
What is Grail Inc’s market cap?
Grail Inc’s market cap is $50.96B.
When is Grail Inc’s upcoming earnings report date?
Grail Inc’s upcoming earnings report date is Nov 18, 2026 which is in 103 days.
How were Grail Inc’s earnings last quarter?
Grail Inc released its earnings results on Aug 05, 2026. The company reported -$44.043 earnings per share for the quarter, beating the consensus estimate of -$45.695 by $1.652.
Is Grail Inc overvalued?
According to Wall Street analysts Grail Inc’s price is currently Undervalued.
Does Grail Inc pay dividends?
Grail Inc does not currently pay dividends.
What is Grail Inc’s EPS estimate?
Grail Inc’s EPS estimate is -45.08.
How many shares outstanding does Grail Inc have?
Grail Inc has 42,916,590 shares outstanding.
What happened to Grail Inc’s price movement after its last earnings report?
Grail Inc reported an EPS of -$44.043 in its last earnings report, beating expectations of -$45.695. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Grail Inc?
Currently, no hedge funds are holding shares in MX:GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,189.55 (44.19% Upside)
$1,189.55 (44.19% Upside)
Blogger Sentiment
Bullish
MX:GRAL Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
65.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.55%
Trailing 12-Months
Company Description
Grail Inc
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
GRAL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive commercial and clinical momentum: strong year-over-year revenue and volume growth, meaningful gross profit improvement, substantial cash including a $110M Samsung strategic investment, and a robust, differentiated clinical evidence base with low false positive rate and high PPV. Key execution items — a completed PMA submission, anticipated FDA advisory committee and sales force expansion — support the company’s pathway to broader access. Offsetting these positives are continued large operating losses and a widened adjusted EBITDA shortfall, the NHS primary endpoint miss, pricing/ASP pressure from channel mix and competitive noise, and timing uncertainty around the FDA advisory committee and U.K. decision-making. Taken together, the highlights (growth, cash runway, unique clinical validation and commercialization readiness) outweigh the lowlights, though execution and regulatory timing risks remain significant.View all MX:GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$1,189.55
▲(44.19% Upside)